Accelerating Drug Development with Causal AI & Digital Twins: Ansys and Nova In Silico Partner for ISCT Solution
Bringing a new drug to market typically takes over a decade and costs between $1.5 to $2.6 billion, yet only about 5% of drug candidates entering clinical trials ultimately receive FDA approval. The high failure rate poses significant scientific and financial challenges. Causal AI has emerged as a promising solution, using mechanistic modeling and AI to inform human trials. To advance this capability, Ansys has partnered with Nova In Silico, a healthtech innovator based in Lyon, France. This collaboration will integrate Nova In Silico’s purpose-built Jinko trial simulation platform with Ansys Granta Data Management, delivering a unified solution to generate digital twins for In Silico Clinical Trials (ISCT). This integrated approach has the potential to significantly reduce R&D costs, accelerate timelines, and enhance clinical success rates across the biopharmaceutical industry.
